Is IMM.L undervalued or overvalued?
As of 2025-03-16, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -7.75 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.29 GBP, the upside of ImmuPharma PLC is -335.81%. This means that IMM.L is overvalued by 335.81%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.75 - -7.75 | -7.75 | -335.81% |
| P/E | (8.77) - (10.92) | (10.17) | -409.7% |
| DDM - Stable | (3.41) - (11.24) | (7.33) | -323.0% |
| DDM - Multi | (2.53) - (6.91) | (3.75) | -214.1% |
| Market Cap (mil) | 16.99 |
| Beta | -0.91 |
| Outstanding shares (mil) | 5.17 |
| Enterprise Value (mil) | 15.91 |
| Market risk premium | 5.98% |
| Cost of Equity | 13.13% |
| Cost of Debt | 5.00% |
| WACC | 8.81% |